Citadel Advisors
EWTX icon

Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Citadel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Buy
44,600
+17,900
+67% +$516K ﹤0.01% 6868
2025
Q4 		$663K Buy
26,700
+7,500
+39% +$151K ﹤0.01% 8334
2025
Q3 		$311K Sell
19,200
-16,300
-46% -$231K ﹤0.01% 10283
2025
Q2 		$465K Buy
35,500
+2,200
+7% +$31.7K ﹤0.01% 8801
2025
Q1 		$733K Sell
33,300
-55,700
-63% -$1.46M ﹤0.01% 7641
2024
Q4 		$2.38M Buy
89,000
+26,200
+42% +$834K ﹤0.01% 5274
2024
Q3 		$1.68M Buy
62,800
+57,500
+1,085% +$1.14M ﹤0.01% 5852
2024
Q2 		$95.5K Sell
5,300
-9,500
-64% -$166K ﹤0.01% 10982
2024
Q1 		$270K Buy
14,800
+8,200
+124% +$130K ﹤0.01% 9698
2023
Q4 		$72.2K Buy
6,600
+6,300
+2,100% +$44.2K ﹤0.01% 11351
2023
Q3 		$1.72K Sell
300
-1,700
-85% -$11.6K ﹤0.01% 13821
2023
Q2 		$15.5K Sell
2,000
-3,700
-65% -$31.2K ﹤0.01% 12943
2023
Q1 		$38K Buy
5,700
+100
+2% +$927 ﹤0.01% 12479
2022
Q4 		$50.1K Buy
+5,600
New +$52.5K ﹤0.01% 12140

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors's EWTX Position: Q1 2026 in Review

Citadel Advisors increased its Edgewise Therapeutics (EWTX) stake by 249% in Q1 2026, buying an estimated $8.82M and bringing the position to 429,032 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

Citadel Advisors first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $77.4M in Q1 2021. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Citadel Advisors held 429,032 shares of Edgewise Therapeutics worth $13.5M as of Q1 2026.
  • Citadel Advisors bought 305,935 Edgewise Therapeutics shares in Q1 2026, an estimated $8.82M.
  • Edgewise Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2823 holding.
  • Citadel Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Edgewise Therapeutics position peaked at $77.4M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.